Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinumbased chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD (18/26) of patients whom responded after 2 cycles proceeded to transplant. Median overall survival was 26 mos (95% CI: 7.3 mos-not reached) and median progression-free survival was 11 mos (95% CI: 6-104 mos). There was no grade 3/4 nephrotoxicity; the rate of grade 3/4 neuropathy was 4%.
| I N T R O D U C T I O N
The most common side effects were myelosuppression and transient sensory peripheral neuropathy. The ORR was 53% (8/15) and there were no increases in serum creatinine. The study by Chau et al enrolled 24 patients with an ORR of 50%, again without nephrotoxicity. 5 Lastly, a study by Sym et al substituted oxaliplatin for cisplatin in the ESHAP regimen achieving a 63% ORR with 33% CR in 27% of patients with relapsed aggressive NHL. 7 The current study was designed in the rituximab-era and replaced cisplatin with oxaliplatin in the R-DHAP regimen. The primary endpoint was the ORR with secondary endpoints of the rate of grade 3 nephrotoxicity and neurotoxicity as well as the percent of patients able to proceed to transplant, overall survival (OS) and progression-free survival (PFS) in all patients, and OS and PFS in patients proceeding to transplant.
| P A T I E NT S A ND M E T H O DS
The study was conducted in the Mayo Clinic Cancer Center Research Consortium (MCCRC) and was approved by the Mayo Clinic Institutional Review Board. All patients signed informed consent prior to enrolling and receiving treatment.
| Patient eligibility
Eligible patients were required to have relapsed CD20 positive B cell NHL with aggressive histology who had not responded to or relapsed after initial chemotherapy and would, if treated off study, be treated with a platinum-containing regimen. Eligible tumor types were diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or transformed lymphoma. A tumor biopsy confirming histology was required within six weeks of registration. Patients were required to have measurable disease (at least one lesion 1.5 3 1.5 CM); performance status 0-2; and 1 prior chemotherapy regimen. External beam radiation therapy was not counted as a regimen. Required hematologic parameters were: absolute neutrophil count 1500/mL, platelet count 75,000/mL, serum creatinine 1.53 the institutional upper limit of normal, and total bilirubin 2 mg/dL. Patients with CNS lymphoma were not eligible.
| Treatment regimen
The treatment regimen included rituximab 375 mg/m 2 IV on days 1, 8, IV in 250 mL of D5W over three hours 3 two doses on days 2-3. The second dose of cytarabine was to be given no sooner than 12 hours after the first dose and no later than 24 hours after the conclusion of the first dose. This permitted outpatient administration if desired.
Patients were provided pegfilgrastim 6 mg SC on day 4. A cycle was 21
days. Subsequent cycles were delivered if the ANC was 1500/mL and the platelet count was 75,000/mL. Patients who did not achieve those parameters were delayed for up to two weeks and received 100% dose if they recovered to the above parameters. Recovery to ANC1000 -1499 or platelet 50,000-74,999 received a 50% dose reduction; those not meeting those requirements went off study.
Patients who developed a creatinine 3 3 UNL had the OAD held for one week. They were allowed to proceed if the creatinine corrected; if not, they were removed from the study. Patients were provided standard of care ancillary treatments and permitted to receive oral magnesium or potassium supplementation to correct hypomagnesemia or hypokalemia during platinum therapy.
| Treatment evaluation
Patients were staged with a computed tomography (CT) scan of the chest, abdomen, and pelvis pretreatment and after cycles 1 and 2 of the regimen. Response was assessed per International Working Group recommendations for response criteria for NHL. were to go off study.
| Statistical design
Descriptive factors recorded are listed in Table 1 . The primary endpoint was ORR after two cycles of ROAD. A response was considered a CR or PR as defined by the IWG. 8 All patients who met the eligibility criteria, signed the consent form and received treatment were considered eligible and evaluable for response. The study goal was to improve the ORR to 70%. At the time the study was written, 50% was considered the standard ORR to platinum-based salvage regimens in patients who had not been treated with rituximab-containing regimens.
This phase II study utilized a one-stage design with an interim analysis based on a Simon optimum design. 9 Forty-five evaluable patients were required to test the null hypothesis that the true ORR for this regimen is at most 50% versus the alternative hypothesis that the true ORR is 70% or greater. The study had 90% power with a 10% Type I error rate. The ORR was estimated by the number of responses after 2 cycles of ROAD divided by the number of evaluable patients. A confidence interval for the true success proportion was calculated using the method of Duffy-Santer. 10 OS in all patients was defined as the time from the date of registration until the date of death due to any cause. PFS was defined as the time from the date of registration until the date of progression or death due to any cause. If a patient received subsequent treatment other than transplant before progression then they were censored for progression on the date of initiation of subsequent treatment. PFS and OS in the subset of patients who received a transplant was defined as the time from the date of transplant until the date of first occurrence of an event (progression or death for PFS; death for OS). The distributions of time to event endpoints were estimated using the KaplanMeier 11 method and patients who were event-free were censored on the date of last follow-up.
Adverse events were graded using the NCI Common Toxicity Criteria (version 3.0). Toxicity was defined as an adverse event classified as being possibly, probably, or definitely related to study treatment. Twenty-six patients completed treatment per the study schema.
Other reasons for going off study included adverse events (2 patients; one with grade 3 sensory neuropathy and one with grade 4 febrile neutropenia and thrombocytopenia), disease progression (8 patients), alternate treatment (5 patients), other medical problems (3 patients; 1 pneumonia, 1 bowel obstruction, 1 unspecified), and physician discretion (1 patient).
| Long-term outcomes
Twenty-four patients (53%) have progressed and 26 patients (58%) have died. Median OS was 26 mos (95% CI: 7.3 mos -not reached, Figure 1 ) and median PFS was 11 mos (95% CI: 6 -104 mos, Figure 2 ). The median follow-up for the 19 patients that remain alive is 61 mos (range, 17-72). Forty-two percent of all patients and 69% of patients transplanted remain alive at 5 years. Cause of death was disease progression for 19 patients; 7 died without evidence of lymphoma-1 patient due to AE (hemorrhagic stroke, definitely related) and 6 due to other reasons (S. aureus infection in one patient unrelated to treatment, cardiopulmonary arrest for 1 patient, CHF for 1 patient, and unknown causes for 3 patients).
| Safety and tolerability
Seven patients experienced dose delays or reductions. Four patients experienced dose delays on 5 cycles due to herpes zoster infection (1 cycle), delay in drug (1 cycle), MD discretion (1 cycle due to delay in starting transplant), holiday (1 cycle), and hospitalization for pneumonia
(1 cycle). Four patients had dose reductions on 6 cycles due to hematologic adverse events (3 cycles), fever/hypotension (1 cycle), and nausea/vomiting (2 cycles). Adverse events without attribution are described in Table 2 . Four patients (9%) had a maximum of grade 3 and 60% (27/45) had a maximum of grade 4 hematology adverse events (AE). For non-hematology AEs, 49% (22/45) of patients had a maximum of grade 3 and 7% (3/45) of patients had a maximum of grade 4. The most common grade 3/4 non-hematologic AEs included febrile neutropenia (18%), fatigue (16%), dehydration (11%), nausea (11%), vomiting (11%), diarrhea (9%), and hypokalemia (9%).
Toxicity (considered by investigators to be possibly, probably, or definitely related to ROAD therapy) is enumerated in Table 3 to 42% for RDHAP. In our study of ROAD, the ORR study goal was achieved with an ORR of 71% and 69% of patients responding after 2 cycles of ROAD proceeded to transplant. These results were achieved in a study population where 96% had received rituximab and 53% were within 1 year of diagnosis. Thus, ROAD appears to produce results similar to R-ICE, R-DHAP, and R-GDP. Like R-GDP, ROAD can be administered as an outpatient which can produce cost-savings.
Another goal of our study was to reduce the risk of serious nephrotoxicity or neurotoxicity that sometimes occurs with other platinum compounds and can impede eligibility for transplantation. Indeed, in this trial we had no grade 3/4 nephrotoxicity that was related to oxaliplatin. With regards to neuropathy, a known problem with oxaliplatin, 12 we encountered it in 2 patients (4%). This low rate is likely due to the limited number of cycles of ROAD in this study compared to its longerterm use in other cancers.
This trial also provides insight into long-term follow-up on these There have been other trials of oxaliplatin in lymphoma. The single institution, retrospective experience of R-DHAX in 42 patients with relapsed DLBCL showed a 58% ORR with 48% CR. 13 There was no nephrotoxicity. The R-DHAX is similar to our ROAD except that the dose of oxaliplatin is lower at 100 mg/m 2 and there is only one dose of rituximab in cycle 1. ROAD was designed to deliver all rituximab in the first cycle to try to maximize the response after 2 cycles. The rituximab,
gemcitabine, oxaliplatin regimen was tested in a phase II study for patients with relapsed/refractory DLBCL who were not candidates for stem cell transplant. 14 There were 49 patients (6 refractory; 43 relapsed) and 63% had received previous rituximab and 35% a previous autologous transplant. The ORR after four cycles was 61% with 44%
CR. Those patients who had received prior rituximab had a 23% ORR.
The ORR was only 18% in patients with a relapse within 12 months of NHL diagnosis. There has been only one study that tested the ICE regimen substituting oxaliplatin for carboplatin finding an ORR of 65% (15/23). 15 No significant renal impairment was observed and patients were able to proceed to transplant. A phase 2 trial treated 46 patients with up to eight cycles of rituximab with gemcitabine and oxaliplatin. 16 The majority of patients (72%) had relapsed DLBCL. The response rate after four cycles was 83%. In patients who had previously received rituximab, the response rate dropped to 65%. The two-year OS was 66%. A recent retrospective review of 44 patients receiving gemcitabine with oxaliplatin off study showed an ORR of 43%. 17 Patients relapsing within 12 months had a worse prognosis with only 8% achieving CR; the median OS was only eight months.
Our study recruited only 4 patients with MCL and the ORR was 75% (3/4). Others have tested gemcitabine/oxaliplatin/rituximab in patients with MCL and also found an excellent ORR of over 80%. 18 The strengths of our study is the long-term follow-up, the study population was relatively high-risk with nearly all patients having received prior rituximab and over half were within 12 months of diagnosis, and the study was conducted in the cooperative-group setting.
The limitations of the study were its relatively small size, lack of randomization, and it was conducted before PET scans were integrated into these types of studies.
It now seems clear that the field of relapsed DLBCL is in need of a new approach to salvage therapy. The platinum-based regimens discussed herein all seem relatively equivalent and thus the clinician can select between them depending on individualized patient features and the desire for inpatient vs outpatient therapy. New therapeutic regimens need to build off of the R-ICE, R-DHAP, R-GDP, or ROAD 
